Northland Securities reissued their buy rating on shares of Venture Life Group (LON:VLG) in a research report report published on Thursday, September 20th.

Separately, Northern Trust Capital Markets reiterated a buy rating and set a GBX 100 ($1.31) price objective on shares of Venture Life Group in a report on Monday, June 18th.

VLG stock remained flat at $GBX 46 ($0.60) during midday trading on Thursday. 4,000 shares of the company traded hands, compared to its average volume of 8,687. Venture Life Group has a 1-year low of GBX 40 ($0.52) and a 1-year high of GBX 90 ($1.18).

About Venture Life Group

Venture Life Group plc develops and commercializes oral care products, food supplements, medical devices, and dermo-cosmetics for the ageing population in the United Kingdom, Europe, and internationally. It operates through Brands, and Development and Manufacturing segments. The company offers Benecol, a cardiovascular product for lowering cholesterol in food supplement; and neurology products, including NeuroAge, NeuroAge Sleep, and NeuroAge NRG food supplements to enhance mental alertness, cognitive function, and mental performance in ageing brain.

Featured Article: Exchange-Traded Funds (ETFs)

Receive News & Ratings for Venture Life Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Venture Life Group and related companies with's FREE daily email newsletter.